Positive results prompt AstraZeneca to end Crestor trial

03/31/2008 | Wall Street Journal (free content), The · USA Today

AstraZeneca on Monday announced it will halt a trial of Crestor earlier than scheduled after results showed the cholesterol-lowering drug had significant advantages over placebo. The study found Crestor effective in lowering the risk of major cardiovascular events in patients with high levels of C-reactive protein, which has been associated with heart problems.

View Full Article in:

Wall Street Journal (free content), The · USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID